SO SÁNH TỶ LỆ ĐÁP ỨNG CỦA PHÁC ĐỒ PEMETREXED-CARBOPLATIN VỚI PHÁC ĐỒ PACLITAXEL-CARBOPLATIN TRÊN BỆNH NHÂN CAO TUỔI UNG THƯ BIỂU MÔ TUYẾN CỦA PHỔI GIAI ĐOẠN IV

Abstract

In Vietnam, lung cancer is often diagnosed at metastatic stage (60-70%), Platinum-based doublet chemotherapy plays an important role at this stage. Objectives: describe clinical, subclinical features and compare the response rate of the Pemetrexed-Carboplatin regimen with the Paclitaxel-Carboplatin for elderly patients with adenocarcinoma at the IV stage of lung cancer. Methods: the cross-sectional, description, retrospective have been carried on 88 patients was treated at K hospital and Huu Nghi hospital from 01/2016 to 12/2020. Results compare the Pemetrexed-Carboplatin regimen with the Paclitaxel-Carboplatin regimen: mean age of 67 (60-74) vs 68 (60-77); male/female ratio = 2,7/1 vs 5,4/1. Smoking rate is 66,2% vs 62.7%; patients have comorbidity 78% vs 37,3%; patients suffer from cardiovascular diseases 56,8% vs 15,7%. Common symptoms include persistent coughing (67,6% vs 39,2%); chest pain (48,6% vs 23,5%). Tumors are more commonly found in the right lung and upper lobes of the lung. Lung cancer often spreads to pleura – pericardium, adrenal glands, both lungs and bones. ORR is 35,1% vs 35,5%; DCR is 59,5% vs 74,5%. Conclusion: The Pemetrexed-Carboplatin and Paclitaxel-Carboplatin regimens treating elderly patients with stage IV lung adenocarcinoma have the same response rate as other regimens.